$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000104746914001433 Filed on February 27, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue			$0.00
YoY Change
Gross Profit			$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.000M	$3.730M	$13.33M
YoY Change	20.0%	109.55%	84.91%
% of Gross Profit
Research & Development	$4.652M	$7.280M	$15.80M
YoY Change	73.58%	199.59%	149.91%
% of Gross Profit
Depreciation & Amortization	$66.00K	$60.00K	$231.0K
YoY Change	40.43%	50.0%	148.39%
% of Gross Profit
Operating Expenses	$7.650M	$11.01M	$29.13M
YoY Change	47.83%	161.52%	115.34%
Operating Profit	-$7.650M		-$29.13M
YoY Change	47.83%		115.34%
Interest Expense	-$150.0K	$10.00K	$90.00K
YoY Change	-850.0%	-50.0%	350.0%
% of Operating Profit
Other Income/Expense, Net	-$10.00K		$0.00
YoY Change
Pretax Income	-$7.810M	-$11.00M	-$29.04M
YoY Change	51.36%	162.53%	114.98%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.814M	-$11.00M	-$29.04M
YoY Change	51.52%	162.53%	114.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$86.77	-$137.50	-$414.90
COMMON SHARES
Basic Shares Outstanding	18.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$89.50M	$44.40M	$44.40M
YoY Change	49.92%	41.4%	41.4%
Cash & Equivalents	$56.13M	$18.08M	$18.10M
Short-Term Investments	$33.30M	$26.30M	$26.30M
Other Short-Term Assets	$600.0K	$700.0K	$700.0K
YoY Change	20.0%	16.67%	16.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$90.07M	$45.08M	$45.10M
YoY Change	49.66%	41.02%	40.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.202M	$880.0K	$900.0K
YoY Change	34.3%	16.4%	12.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.403M	$1.500M	$1.500M
YoY Change
Other Assets	$100.0K	$100.0K	$100.0K
YoY Change	13.64%	7.53%	0.0%
Total Long-Term Assets	$2.693M	$2.468M	$2.400M
YoY Change	173.96%	190.69%	200.0%
TOTAL ASSETS
Total Short-Term Assets	$90.07M	$45.08M	$45.10M
Total Long-Term Assets	$2.693M	$2.468M	$2.400M
Total Assets	$92.76M	$47.55M	$47.50M
YoY Change	51.66%	44.89%	44.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.943M	$1.654M	$1.700M
YoY Change	104.96%	89.03%	88.89%
Accrued Expenses	$4.344M	$4.120M	$4.100M
YoY Change	279.06%	240.21%	241.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.287M	$5.774M	$5.800M
YoY Change	200.24%	176.8%	176.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$74.00K	$70.00K	$100.0K
YoY Change	572.73%	900.0%
Total Long-Term Liabilities	$74.00K	$70.00K	$100.0K
YoY Change	572.73%	900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.287M	$5.774M	$5.800M
Total Long-Term Liabilities	$74.00K	$70.00K	$100.0K
Total Liabilities	$6.361M	$5.844M	$5.800M
YoY Change	202.19%	179.22%	176.19%
SHAREHOLDERS EQUITY
Retained Earnings		-$45.18M
YoY Change		180.02%
Common Stock	$23.00K	$18.00K
YoY Change	27.78%	38.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$86.40M	$41.70M	$41.70M
YoY Change
Total Liabilities & Shareholders Equity	$92.76M	$47.55M	$47.50M
YoY Change	51.66%	44.89%	44.82%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013
OPERATING ACTIVITIES
Net Income	-$7.814M	-$11.00M	-$29.04M
YoY Change	51.52%	162.53%	114.98%
Depreciation, Depletion And Amortization	$66.00K	$60.00K	$231.0K
YoY Change	40.43%	50.0%	148.39%
Cash From Operating Activities	-$4.960M	-$4.680M	-$18.09M
YoY Change	22.17%	34.1%	62.13%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$210.0K	$719.0K
YoY Change	-100.0%	40.0%	-15.31%
Acquisitions
YoY Change
Other Investing Activities	-$8.640M	$1.970M	-$10.30M
YoY Change		-111.8%	-38.65%
Cash From Investing Activities	-$8.640M	$1.760M	-$11.02M
YoY Change	4700.0%	-110.45%	-37.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$51.70M		$32.41M
YoY Change	58.1%		702.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	51.66M	-80.00K	$32.41M
YoY Change	58.22%	300.0%	-16.95%
NET CHANGE
Cash From Operating Activities	-4.960M	-4.680M	-$18.09M
Cash From Investing Activities	-8.640M	1.760M	-$11.02M
Cash From Financing Activities	51.66M	-80.00K	$32.41M
Net Change In Cash	38.06M	-3.000M	$3.302M
YoY Change	33.97%	-85.26%	-67.72%
FREE CASH FLOW
Cash From Operating Activities	-$4.960M	-$4.680M	-$18.09M
Capital Expenditures	$0.00	$210.0K	$719.0K
Free Cash Flow	-$4.960M	-$4.890M	-$18.81M
YoY Change	16.87%	34.34%	56.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1211000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5774000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2086000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	70000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	5844000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	2093000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1170000	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86851000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	46848000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16134000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	41701000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	30721000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47545000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32814000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1454000	USD
	us-gaap	Operating Expenses OperatingExpenses	2624000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2624000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-101000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2624000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45178000	USD
CY2013Q4	ovas	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsNumberOfSecurities	8	item
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-17640000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36455000	USD
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18078000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14776000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	26349000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	16615000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	650000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	574000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	45077000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	31965000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	880000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	756000	USD
CY2013Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1500000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	88000	USD
CY2013Q4	us-gaap	Assets Assets	47545000	USD
CY2012Q4	us-gaap	Assets Assets	32814000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1654000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	875000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	93000	USD
CY2012Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2.023	pure
CY2013Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	44400000	USD
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18528215	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14268068	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17541126	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12622919	shares
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15802000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6323000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13332000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7206000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21992000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	29134000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	13529000	USD
	us-gaap	Operating Expenses OperatingExpenses	45287000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-29134000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-13529000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45287000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	90000	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	109000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-29044000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-13510000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-101000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29044000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13510000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45279000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.80
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.42
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16160000	shares
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5810000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8350000	shares
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29028000	USD
	ovas	Convertible Preferred Stock Issued During Period Value New Issues ConvertiblePreferredStockIssuedDuringPeriodValueNewIssues	-101000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13516000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45168000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-2377000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	USD
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	88000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	276000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	41091000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32414000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	6099000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-11018000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-28658000	USD
CY2013	us-gaap	Transfer To Investments TransferToInvestments	1500000	USD
CY2012	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	34992000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4039000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	32414000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	39031000	USD
CY2012	ovas	Common Shares Value Attributable To Conversion Of Preferred Stock Series A CommonSharesValueAttributableToConversionOfPreferredStockSeriesA	6200000	USD
CY2012	ovas	Common Shares Value Attributable To Conversion Of Preferred Stock Series B CommonSharesValueAttributableToConversionOfPreferredStockSeriesB	34992000	USD
CY2012	ovas	Stock Issued Value Private Placement Basis StockIssuedValuePrivatePlacementBasis	4039000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	347000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1382000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	231000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	93000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	586000	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	77000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	663000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	5094000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1382000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6822000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	76000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	530000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	650000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-721000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	599000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	154000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2972000	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	733000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4191000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18094000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11156000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30810000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	719000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	849000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1568000	USD
CY2013	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15974000	USD
CY2012	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	16698000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	32672000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-5000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	93000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	77546000	USD
CY2012	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	41192000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	41192000	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3302000	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	10235000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	18078000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4541000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000	USD
CY2012Q4	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	14776000	USD
CY2012Q4	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	14776000	USD
CY2013Q4	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	18078000	USD
CY2013Q4	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	18078000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	44417000	USD
CY2012Q4	ovas	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsNumberOfSecurities	15	item
CY2012Q4	ovas	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	11000	USD
CY2012Q4	ovas	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	5000	USD
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	31391000	USD
CY2012Q4	ovas	Cash Cash Equivalents And Marketable Securities Amortized Cost CashCashEquivalentsAndMarketableSecuritiesAmortizedCost	31397000	USD
CY2012Q4	ovas	Cash Cash Equivalents And Marketable Securities Fair Value CashCashEquivalentsAndMarketableSecuritiesFairValue	31391000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	14776000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	41000	USD
CY2012Q3	ovas	Number Classes Board Of Directors NumberClassesBoardOfDirectors	3	item
CY2012Q3	ovas	Staggered Term Board Of Directors StaggeredTermBoardOfDirectors	P3Y
CY2012Q3	ovas	Percentage Of Capital Stock Holders Whose Affirmative Vote Is Required To Remove Directors PercentageOfCapitalStockHoldersWhoseAffirmativeVoteIsRequiredToRemoveDirectors	0.75	pure
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8800000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	93000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	688000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0542	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0231	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0109	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4050	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0528	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0000	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0278	pure
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3664	pure
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5527000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	153000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	142000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-23000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5928000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5928000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12939000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	823000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1602000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	350000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17668000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17668000	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	719000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2725000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	909000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.00
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	471000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3496000	shares
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4120000	USD
CY2013Q4	ovas	Number Of Principal Stockholders For Which Chief Executive Officer Serves As A General Partner NumberOfPrincipalStockholdersForWhichChiefExecutiveOfficerServesAsAGeneralPartner	1	item
CY2011Q4	ovas	Number Of Principal Stockholders From Whom Entity Has Leased Office Space NumberOfPrincipalStockholdersFromWhomEntityHasLeasedOfficeSpace	1	item
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD
CY2013Q2	dei	Entity Public Float EntityPublicFloat	97000000	USD
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18563215	shares
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3055000	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
	us-gaap	Net Income Loss NetIncomeLoss	-2624000	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	USD
CY2013	ovas	Issuance Of Common Stock For Technology Access Fee IssuanceOfCommonStockForTechnologyAccessFee	2500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	324000	USD
CY2013	ovas	Stock Issued Value Under Collaborative Arrangement StockIssuedValueUnderCollaborativeArrangement	2500000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6002000	shares
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	364000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	346000	USD
	ovas	Issuance Of Common Stock For Technology Access Fee IssuanceOfCommonStockForTechnologyAccessFee	2500000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	44000	USD
CY2013	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5670000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	486000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1560000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5670000	USD
	us-gaap	Transfer To Investments TransferToInvestments	1500000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6101000	USD
CY2013	ovas	Stock Issued Value Private Placement Basis StockIssuedValuePrivatePlacementBasis	32656000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5094000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	16000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	4541000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	0	USD
CY2013	us-gaap	Asset Impairment Charges AssetImpairmentCharges	364000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-285000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	31397000	USD
CY2013Q4	ovas	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	13000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	44427000	USD
CY2013Q4	ovas	Cash Cash Equivalents And Marketable Securities Amortized Cost CashCashEquivalentsAndMarketableSecuritiesAmortizedCost	44417000	USD
CY2013Q4	ovas	Cash Cash Equivalents And Marketable Securities Fair Value CashCashEquivalentsAndMarketableSecuritiesFairValue	44427000	USD
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0547	pure
	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0170	pure
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0393	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3724	pure
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3496000	shares
CY2012Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	129000	USD
CY2013Q4	ovas	Accrued Technology Access Fee Payable Current AccruedTechnologyAccessFeePayableCurrent	2186000	USD
CY2013Q4	ovas	Accrued Preclinical Clinical And Contract Manufacturing Current AccruedPreclinicalClinicalAndContractManufacturingCurrent	258000	USD
CY2012Q4	ovas	Accrued Preclinical Clinical And Contract Manufacturing Current AccruedPreclinicalClinicalAndContractManufacturingCurrent	93000	USD
CY2013Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	174000	USD
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Concentrations of Risk</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        We have no significant off-balance sheet risk.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        Cash, cash equivalents and marketable securities are the only financial instruments we have that are subject to concentration of credit risk. Cash and cash equivalents are primarily maintained with two major financial institutions in the United States. Deposits at banks may exceed the insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. Short-term investments consistent of investment grade corporate debt securities. Our investment policy, which has been approved by our board of directors, limits the amount we may invest in any one issuer of investments, thereby reducing credit risk concentrations.</font></p> </div>
CY2013Q4	ovas	Collaborative Arrangements Technology Access Fee Payable In Cash Upon Specified Passage Of Time CollaborativeArrangementsTechnologyAccessFeePayableInCashUponSpecifiedPassageOfTime	2500000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11700000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2011	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1954000	USD
CY2013Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	605000	USD
CY2012Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	330000	USD
CY2012Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	139000	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2012Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	ovas	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	3000	USD
CY2013	ovas	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerNumberOfSecurities	0	item
CY2012	ovas	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerNumberOfSecurities	0	item
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	9500000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	11600000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	USD
CY2012Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2012Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	18078000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD

Files In Submission

Name	View Source	Status
0001047469-14-001433-index-headers.html	Edgar Link	pending
0001047469-14-001433-index.html	Edgar Link	pending
0001047469-14-001433.txt	Edgar Link	pending
0001047469-14-001433-xbrl.zip	Edgar Link	pending
a2218414z10-k.htm	Edgar Link	pending
a2218414zex-10_12.htm	Edgar Link	pending
a2218414zex-10_13.htm	Edgar Link	pending
a2218414zex-10_14.htm	Edgar Link	pending
a2218414zex-10_15.htm	Edgar Link	pending
a2218414zex-10_24.htm	Edgar Link	pending
a2218414zex-10_34.htm	Edgar Link	pending
a2218414zex-10_35.htm	Edgar Link	pending
a2218414zex-10_36.htm	Edgar Link	pending
a2218414zex-21_1.htm	Edgar Link	pending
a2218414zex-23_1.htm	Edgar Link	pending
a2218414zex-31_1.htm	Edgar Link	pending
a2218414zex-31_2.htm	Edgar Link	pending
a2218414zex-32_1.htm	Edgar Link	pending
a2218414zex-32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g117623.jpg	Edgar Link	pending
g29982ksi001.jpg	Edgar Link	pending
g29982ksi002.jpg	Edgar Link	pending
g29982kui001.jpg	Edgar Link	pending
g29982kui002.jpg	Edgar Link	pending
g29982kwi001.jpg	Edgar Link	pending
g29982kwi002.jpg	Edgar Link	pending
g29982kyi001.jpg	Edgar Link	pending
g29982kyi002.jpg	Edgar Link	pending
g29982lai001.jpg	Edgar Link	pending
g608387.jpg	Edgar Link	pending
ovas-20131231.xml	Edgar Link	completed
ovas-20131231.xsd	Edgar Link	pending
ovas-20131231_cal.xml	Edgar Link	unprocessable
ovas-20131231_def.xml	Edgar Link	unprocessable
ovas-20131231_lab.xml	Edgar Link	unprocessable
ovas-20131231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2014 Q1 Form 10-K Financial Statement

#000104746914001433 Filed on February 27, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2014 Q1 Form 10-K Financial Statement

#000104746914001433 Filed on February 27, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst